WO2012053856A3 - Respiratory syncytial virus vaccine composition and method for preparing same - Google Patents

Respiratory syncytial virus vaccine composition and method for preparing same Download PDF

Info

Publication number
WO2012053856A3
WO2012053856A3 PCT/KR2011/007882 KR2011007882W WO2012053856A3 WO 2012053856 A3 WO2012053856 A3 WO 2012053856A3 KR 2011007882 W KR2011007882 W KR 2011007882W WO 2012053856 A3 WO2012053856 A3 WO 2012053856A3
Authority
WO
WIPO (PCT)
Prior art keywords
rsv
vaccine
preventing
protein
respiratory diseases
Prior art date
Application number
PCT/KR2011/007882
Other languages
French (fr)
Korean (ko)
Other versions
WO2012053856A2 (en
Inventor
장준
송만기
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Publication of WO2012053856A2 publication Critical patent/WO2012053856A2/en
Publication of WO2012053856A3 publication Critical patent/WO2012053856A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a vaccine composition for preventing and treating respiratory diseases induced by respiratory syncytial virus (RSV), and a method for preparing same. More specifically, the present invention relates to a procaryotic cell expression vector for preparing a vaccine for treating or preventing respiratory diseases induced by RSV, the procaryotic cell expression vector comprising a nucleic acid sequence for coding a whole or a part of a peptide fragment having an amino acid 120th to 230th from an N-terminal of RSV G protein; a procaryotic cell transformant for preparing the vaccine for preventing and treating respiratory diseases induced by RSV, the procaryotic transformant being transformed by the expression vector; a method for preparing a peptide fragment of RSV G protein for the vaccine for preventing and treating respiratory diseases induced by RSV, the method using the procaryotic transformant; a vaccine composition for preventing and treating respiratory diseases induced by RSV, the vaccine composition comprising a whole or a part of the peptide fragment having an amino acid 120th to 230th from the N-terminal of the RSV G protein; and a method for preventing or treating respiratory diseases due to RSV infection, the method comprising a step for administering the vaccine composition to a subject. The vaccine comprising procaryotic cell expression RSV G protein fragment according to the present invention induces very high blood serum IgG and respiratory mucosa IgA from just two immunizations, and displays effective defense against RSV replication without showing eosinophilic immunopathological effect due to the vaccine at the time of an RSV infection. Also, the present invention has very high economic efficiency as the vaccine uses a protein purified from bacteria, and resolves the problem of stability that can result from a virus vaccine by using a purified protein fragment as the vaccine having antigenicity, thereby making the present invention advantageous considering that the main subjects of RSV vaccine immunization are newborn and infants. Also, the present invention shows sufficient immunity even from sublingual administration, which has superior stability, and therefore, has an effect of increasing the stability of vaccine immunization.
PCT/KR2011/007882 2010-10-21 2011-10-21 Respiratory syncytial virus vaccine composition and method for preparing same WO2012053856A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0102976 2010-10-21
KR20100102976 2010-10-21

Publications (2)

Publication Number Publication Date
WO2012053856A2 WO2012053856A2 (en) 2012-04-26
WO2012053856A3 true WO2012053856A3 (en) 2012-08-02

Family

ID=45975759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007882 WO2012053856A2 (en) 2010-10-21 2011-10-21 Respiratory syncytial virus vaccine composition and method for preparing same

Country Status (2)

Country Link
KR (1) KR101366702B1 (en)
WO (1) WO2012053856A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101366702B1 (en) 2010-10-21 2014-02-28 이화여자대학교 산학협력단 Vaccine composition for respiratory syncytial virus and manufacturing method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117070562B (en) * 2023-08-16 2024-03-26 北京华诺泰生物医药科技有限公司 Recombinant respiratory syncytial virus protein vaccine and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040071678A (en) * 2001-09-28 2004-08-12 유니버시티 오브 사우스 플로리다 Rsv gene expression vaccine
KR20090031053A (en) * 2007-09-21 2009-03-25 이화여자대학교 산학협력단 Respiratory syncytial virus vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512662A (en) 1997-07-18 2001-08-28 コノート ラボラトリーズ リミテッド Nucleic acid vaccine encoding G protein of respiratory syncytial virus
KR101366702B1 (en) * 2010-10-21 2014-02-28 이화여자대학교 산학협력단 Vaccine composition for respiratory syncytial virus and manufacturing method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040071678A (en) * 2001-09-28 2004-08-12 유니버시티 오브 사우스 플로리다 Rsv gene expression vaccine
KR20090031053A (en) * 2007-09-21 2009-03-25 이화여자대학교 산학협력단 Respiratory syncytial virus vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAE-RANG YU ET AL.: "Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection", J. VIROL., vol. 82, 2008, pages 2350 - 2357 *
YAN HUANG ET AL.: "A single amino acid substitution in a recombinant G prote in vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV)", VACCINE, vol. 21, no. 19-20, 2003, pages 2500 - 2505 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101366702B1 (en) 2010-10-21 2014-02-28 이화여자대학교 산학협력단 Vaccine composition for respiratory syncytial virus and manufacturing method thereof

Also Published As

Publication number Publication date
KR101366702B1 (en) 2014-02-28
KR20120047780A (en) 2012-05-14
WO2012053856A2 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
CN107847580B (en) Vaccines against RSV
US20190142951A1 (en) Influenza antigen delivery vectors and constructs
Hong et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection
US9060975B2 (en) Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
HRP20160798T1 (en) Recombinant rsv antigens
MX2019006349A (en) Novel recombinant prefusion rsv f proteins and uses thereof.
JP6735269B2 (en) Influenza virus vaccine and its use
IL276210B2 (en) Mers-cov vaccine
RU2016146801A (en) VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS
US20240067681A1 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
US9963490B2 (en) Influenza nucleoprotein vaccines
US20230310581A1 (en) A live attenuated measles virus vectored vaccine for sars-cov-2
JP2015500827A5 (en)
JP2013518052A5 (en)
JP2015525794A5 (en)
Tomčíková et al. Different mechanisms of the protection against influenza A infection mediated by broadly reactive HA2-specific antibodies
WO2012053856A3 (en) Respiratory syncytial virus vaccine composition and method for preparing same
WO2011017442A3 (en) Anti-rsv immunogens and methods of immunization
US20240181034A1 (en) Human metapneumo virus vaccine
WO2014185817A3 (en) Vaccine for the prophylaxis and treatment of rotavirus infection with a fusion protein as active agent (variants)
Kim et al. Mucosal immunization with recombinant adenovirus encoding soluble globular head of hemagglutinin protects mice against lethal influenza virus infection
JP7167088B2 (en) Influenza virus vaccine and its use
WO2011109106A3 (en) Immunogenic compositions against human progastrin peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11834656

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11834656

Country of ref document: EP

Kind code of ref document: A2